Ben Izar's lab is a pioneer in combining single cell techniques, genome-editing, and systems biology to explore the cancer field’s most pressing problems.
Including BRCA1 testing with prenatal carrier screening could identify people at risk of breast, ovarian, and pancreatic cancer at a time when cancer screening could save their lives.
A study from Columbia researchers suggests that changing a single letter in the DNA code of selected genes in T cells may supercharge cell therapies against cancer.
Director of the National Cancer Institute, Harold Varmus, MD'66, talked about the challenges and goals of precision medicine's efforts to tackle cancer.
Household net worth is a major and overlooked factor in adherence to hormonal therapy among breast cancer patients and partially explains racial disparities in quality of care.
The drug Gleevec is well known not only for its effectiveness against leukemia. A similar drug might be able to tame some brain cancers, new research from Columbia University Medical Center has shown.
Two Columbia University Medical Center faculty members were present today when President Obama provided details of the precision medicine initiative he announced during this year’s State of the Union address.